Moo-Hyun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8841325/publications.pdf

Version: 2024-02-01

144 papers 1,886 citations

394421 19 h-index 315739 38 g-index

209 all docs

209 docs citations

times ranked

209

2817 citing authors

#	Article	IF	Citations
1	Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. Journal of Atherosclerosis and Thrombosis, 2022, 29, 850-865.	2.0	5
2	Clinical Results of Drug-Coated Balloon Treatment in a Large-Scale Multicenter Korean Registry Study. Korean Circulation Journal, 2022, 52, .	1.9	3
3	SuperCrossâ,,¢ Microcatheter Is an Excellent Solution for PCI With Complex and Tortuous Coronary Anatomy. , 2022, 1, 82.		O
4	Comparison of the radiation dose between dual-acquisition coronary computed tomography and coronary angiography for coronary spasm. Kosin Medical Journal, 2022, 37, 46-51.	0.3	0
5	Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium. Yonsei Medical Journal, 2022, 63, 413.	2.2	13
6	Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 2480.	2.4	2
7	Assessment of coronary spasms with transluminal attenuation gradient in coronary computed tomography angiography. PLoS ONE, 2022, 17, e0271189.	2.5	1
8	Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. Thrombosis and Haemostasis, 2021, 121, 1151-1160.	3.4	12
9	Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. Journal of Atherosclerosis and Thrombosis, 2021, 28, 124-136.	2.0	7
10	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thrombosis and Haemostasis, 2021, 121, 422-432.	3.4	149
11	Prognostic effect of increased left ventricular wall thickness in severe aortic stenosis. Cardiovascular Ultrasound, 2021, 19, 5.	1.6	6
12	Drug-coated balloon treatment for nonsmall de-novo coronary artery disease: angiographic and clinical outcomes. Coronary Artery Disease, 2021, 32, 534-540.	0.7	4
13	Contemporary Status of Acute Myocardial Infarction in Korean Patients: Korean Registry of Acute Myocardial Infarction for Regional Cardiocerebrovascular Centers. Journal of Clinical Medicine, 2021, 10, 498.	2.4	10
14	Hybrid cardiac imaging-guided optimal management of right anomalous coronary artery origin from the opposite sinus with interarterial course (R-ACAOS): a case report. European Heart Journal - Case Reports, 2021, 5, ytab210.	0.6	1
15	Comparison of Performance between ARC-HBR Criteria and PRECISE-DAPT Score in Patients Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2021, 10, 2566.	2.4	5
16	Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. Journal of Clinical Medicine, 2021, 10, 2699.	2.4	11
17	Comparison of the Efficacy and Safety of Atorvastatin 40 mg/i‰-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study. Clinical Therapeutics, 2021, 43, 1419-1430.	2.5	3
18	Late lumen enlargement and plaque regression after drug-coated balloon treatment for an isolated ostial lesion of a diagonal branch. Cardiology Journal, 2021, 28, 632-633.	1.2	0

#	Article	IF	CITATIONS
19	Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clinical Therapeutics, 2021, 43, 1573-1589.	2.5	7
20	A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension. Clinical Therapeutics, 2021, 43, 1746-1756.	2.5	O
21	A Case of Aneurysm Occurring at the Dissection Site after Intervention with Drug-Coated Balloon. Korean Circulation Journal, 2021, 51, 376.	1.9	0
22	Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics. Thrombosis Research, 2021, 209, 115-116.	1.7	0
23	Predicting bleeding risk by simplified PRECISE-DAPT score. Thrombosis Research, 2020, 195, 72-73.	1.7	3
24	Anticoagulant Therapy in Initially Lowâ€Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. Journal of the American Heart Association, 2020, 9, e016271.	3.7	5
25	Efficacy and safety of coâ€administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. Journal of Clinical Hypertension, 2020, 22, 1835-1845.	2.0	7
26	Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Journal of Therapeutics, 2020, 27, e563-e572.	0.9	5
27	Multicenter experience with percutaneous coronary intervention for chronic total occlusion in Korean population: analysis of the Korean nationwide multicenter chronic total occlusion registry. Coronary Artery Disease, 2020, 31, 319-326.	0.7	3
28	Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients. Circulation: Cardiovascular Interventions, 2020, 13, e008525.	3.9	4
29	Less Myocardial Infarction and Stroke Hospitalizations During Middle East Respiratory Syndrome Coronavirus Epidemic in Korea. American Journal of Cardiology, 2020, 132, 176-178.	1.6	0
30	One-year clinical outcomes of coronary chronic total occlusion intervention in patients with acute coronary syndrome versus stable angina: from the Korean chronic total occlusion registry. Coronary Artery Disease, 2020, 31, 430-437.	0.7	2
31	Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). International Journal of Cardiology, 2020, 305, 11-17.	1.7	4
32	A case of drug-coated balloon treatment for two total occluded lesions in a patient with acute coronary syndrome. Cardiology Journal, 2020, 27, 320-321.	1.2	1
33	The Effects of a Vasodilator on Transluminal Attenuation Gradient at Coronary Computed Tomography Angiography. Korean Journal of Radiology, 2020, 21, 1285.	3.4	3
34	Community-Based Pre-Hospital Electrocardiogram Transmission Program for Reducing Systemic Time Delay in Acute ST-Segment Elevation Myocardial Infarction. Korean Circulation Journal, 2020, 50, 709.	1.9	3
35	Severe multivessel coronary artery spasm detected by computed tomography: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	1
36	De-Escalation of Dual Antiplatelet Regimens in East Asian Patients Undergoing Coronary Intervention. American Journal of Therapeutics, 2020, 27, e611-e612.	0.9	2

#	Article	IF	CITATIONS
37	A left main disease repeatedly treated with drug-coated balloon in a patient with poor adherence to medications. Cardiology Journal, 2020, 27, 445-446.	1.2	0
38	Long-Term Outcomes of Unprotected Left Main Coronary Artery Disease: Comparison of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention. Journal of Invasive Cardiology, 2020, 32, 111-116.	0.4	1
39	Comparison of factors affecting platelet reactivity in various platelet function tests. Platelets, 2019, 30, 631-636.	2.3	18
40	Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial. Trials, 2019, 20, 389.	1.6	3
41	Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management. Circulation, 2019, 140, 1865-1877.	1.6	138
42	Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices. Circulation: Cardiovascular Interventions, 2019, 12, e008105.	3.9	25
43	Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation, 2019, 139, 1674-1683.	1.6	241
44	Left ventricular geometric patterns in patients with type A aortic dissection. Cardiovascular Ultrasound, 2019, 17, 2.	1.6	3
45	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. Thrombosis and Haemostasis, 2019, 119, 355-357.	3.4	12
46	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 210-215.	3.0	7
47	Relationship Between Platelet Reactivity and Periprocedural Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. Journal of Invasive Cardiology, 2019, 31, E369-E375.	0.4	1
48	Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. Clinical Therapeutics, 2018, 40, 676-691.e1.	2.5	21
49	Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 142-143.	3.0	1
50	Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 6-9.	3.0	8
51	Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial. Journal of Cardiovascular Translational Research, 2018, 11, 42-49.	2.4	7
52	Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 69-71.	3.0	6
53	Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells. Acta Cardiologica, 2018, 73, 13-18.	0.9	2
54	Chronic total occlusion intervention of the non-infarct-related artery in acute myocardial infarction patients. Coronary Artery Disease, 2018, 29, 495-501.	0.7	12

#	Article	IF	CITATIONS
55	Performance comparison between multienzymes loaded single and dual electrodes for the simultaneous electrochemical detection of adenosine and metabolites in cancerous cells. Biosensors and Bioelectronics, 2018, 109, 263-271.	10.1	12
56	Impact of marital status on outcomes following ST-segment elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2018, 19, 237-240.	0.8	4
57	Clinical factors associated with the development of atrial fibrillation in the year following STEMI treated by primary PCI. Journal of Cardiology, 2018, 71, 125-128.	1.9	16
58	Assessing Vessel Tone during Coronary Artery Spasm by Dual-Acquisition Multidetector Computed Tomography Angiography. Cardiology, 2018, 139, 25-32.	1.4	10
59	Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. American Heart Journal, 2018, 197, 35-42.	2.7	30
60	Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible. TH Open, 2018, 02, e28-e32.	1.4	1
61	Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy. TH Open, 2018, 02, e399-e406.	1.4	2
62	Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2018, 11, e006837.	3.9	39
63	Changes in mitral annular velocities after cardioversion of atrial fibrillation. Echocardiography, 2018, 35, 1782-1787.	0.9	3
64	Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance. Cardiology, 2018, 140, 155-162.	1.4	3
65	Transradial versus transfemoral intervention in ST-segment elevation myocardial infarction patients in Korean population. Korean Journal of Internal Medicine, 2018, 33, 716-726.	1.7	8
66	Noninvasive detection of coronary vasospastic angina using a double-acquisition coronary CT angiography protocol in the presence and absence of an intravenous nitrate: a pilot study. European Radiology, 2017, 27, 1136-1147.	4.5	15
67	Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths. American Journal of Medicine, 2017, 130, e245-e246.	1.5	8
68	Inhibition of Angiotensin Ilâ€Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice. Lipids, 2017, 52, 415-422.	1.7	13
69	A disposable amperometric dual-sensor for the detection of hemoglobin and glycated hemoglobin in a finger prick blood sample. Biosensors and Bioelectronics, 2017, 91, 128-135.	10.1	67
70	CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions. EBioMedicine, 2017, 21, 213-217.	6.1	3
71	A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Cardiology, 2017, 138, 201-206.	1.4	3
72	Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting. TH Open, 2017, 01, e101-e105.	1.4	3

#	Article	IF	CITATIONS
73	Bioresorbable Vascular Scaffold Korean Expert Panel Report. Korean Circulation Journal, 2017, 47, 795.	1.9	6
74	Long-term clinical outcomes after successful and failed recanalization to native chronic Total occlusion: Insights from the Busan chronic Total occlusion (B-CTO) Registry. Cardiovascular Revascularization Medicine, 2016, 17, 229-232.	0.8	4
75	A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. Clinical Therapeutics, 2016, 38, 1485-1497.	2.5	11
76	Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?. International Journal of Cardiology, 2016, 215, 372-376.	1.7	17
77	Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study. International Journal of Cardiology, 2016, 222, 639-644.	1.7	4
78	Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. Clinical Cardiology, 2016, 39, 385-390.	1.8	13
79	A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. Clinical Therapeutics, 2016, 38, 2159-2170.	2.5	10
80	The changes of individual carotid artery wall layer by aging and carotid intimaâ€media thickness value for high risk. Cardiovascular Therapeutics, 2016, 34, 397-403.	2.5	11
81	From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research― Basic Research in Cardiology, 2016, 111, 69.	5.9	41
82	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. International Journal of Cardiology, 2016, 207, 128-131.	1.7	7
83	Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials. JAMA Internal Medicine, 2016, 176, 257.	5.1	20
84	Gender differences in plaque characteristics of culprit lesions in patients with ST elevation myocardial infarction. Heart and Vessels, 2016, 31, 1767-1775.	1.2	12
85	Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 145-151.	3.0	23
86	The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. International Journal of Cardiology, 2016, 205, 13-16.	1.7	1
87	Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy. International Journal of Cardiology, 2016, 203, 877-881.	1.7	4
88	Vorapaxar and optimal aspirin dose: The FDA outlook. International Journal of Cardiology, 2016, 203, 903-905.	1.7	2
89	Falsely high Bâ€type natriuretic peptide concentration in patients without heart failure attributed to AxSYM assay: case series of eight subjects. ESC Heart Failure, 2015, 2, 37-39.	3.1	2
90	Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2015, 79, 1248-1254.	1.6	20

#	Article	IF	CITATIONS
91	Comparison of Prolonged Atrial Electromechanical Delays with Different Definitions in the Discrimination of Patients with Non-Valvular Paroxysmal Atrial Fibrillation. Korean Circulation Journal, 2015, 45, 479.	1.9	1
92	Ventricular Septal Rupture in a Case Suspected as Stress Induced Cardiomyopathy. Journal of Cardiovascular Imaging, 2015, 23, 173.	0.8	1
93	Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30day mortality in patients with ST-elevated myocardial infarction. International Journal of Cardiology, 2015, 195, 104-110.	1.7	12
94	Is Heparin an Acceptable Anticoagulant When Glycoprotein IIb/IIIa Inhibitors AreÂNot Used?. JACC: Cardiovascular Interventions, 2015, 8, 223-224.	2.9	0
95	Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets, 2015, 26, 563-569.	2.3	22
96	Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. Clinical Therapeutics, 2015, 37, 1726-1739.	2.5	2
97	Vorapaxar for secondary stroke prevention: perspectives and obstacles. Expert Review of Neurotherapeutics, 2015, 15, 1377-1382.	2.8	3
98	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?. Expert Review of Cardiovascular Therapy, 2015, 13, 1333-1344.	1.5	7
99	Left Atrial Function Assessed by Left Atrial Strain in Patients with Left Circumflex Branch Culprit Acute Myocardial Infarction. Echocardiography, 2015, 32, 1094-1100.	0.9	5
100	Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy. Korean Circulation Journal, 2014, 44, 386.	1.9	8
101	Association between Cardiac Troponin Level and Coronary Flow Reserve in Patients without Coronary Artery Disease: Insight from a Thermodilution Technique Using an Intracoronary Pressure Wire. Korean Circulation Journal, 2014, 44, 141.	1.9	6
102	Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets, 2014, 25, 292-299.	2.3	25
103	Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI. Platelets, 2014, 25, 285-291.	2.3	6
104	Amniotic mesenchymal stem cells display neurovascular tropism and aid in the recovery of injured peripheral nerves. Journal of Cellular and Molecular Medicine, 2014, 18, 1028-1034.	3.6	32
105	A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart, 2014, 100, 1531-1536.	2.9	40
106	Usefulness of Intravascular Ultrasound Guidance in Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents for Chronic Total Occlusions (from the Multicenter) Tj ETQq0 0 0 rgBT /C	Overlock 1	0 Tef750 137 To
107	Characteristics of circulating CD 31 + cells from patients with coronary artery disease. Journal of Cellular and Molecular Medicine, 2014, 18, 2321-2330.	3.6	14
108	Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, 7.	0.0	2

#	Article	IF	CITATIONS
109	Experience with a Novel Retrograde Wiring Technique for Coronary Chronic Total Occlusion. Journal of Interventional Cardiology, 2013, 26, 254-258.	1.2	9
110	Robust angiogenic properties of cultured human peripheral blood-derived CD31+ cells. International Journal of Cardiology, 2013, 166, 709-715.	1.7	13
111	Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin. Platelets, 2013, 24, 339-347.	2.3	15
112	Pharmacodynamic Comparisons for Single Loading Doses of Prasugrel (30mg) and Clopidogrel (600mg) in Healthy Korean Volunteers. Circulation Journal, 2013, 77, 1253-1259.	1.6	17
113	Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia. Cardiovascular Research, 2012, 93, 525-534.	3.8	75
114	Amniotic Mesenchymal Stem Cells Enhance Wound Healing in Diabetic NOD/SCID Mice through High Angiogenic and Engraftment Capabilities. PLoS ONE, 2012, 7, e41105.	2.5	133
115	Long-Term Results of Silicone Tube Intubation in Patients with Common Canalicular Stenosis. Journal of Korean Ophthalmological Society, 2012, 53, 1373.	0.2	4
116	Combined growth factors enhanced angiogenic potential of cord blood-derived mononuclear cells transplanted to ischemic limbs. Journal of Molecular and Cellular Cardiology, 2011, 51, 702-712.	1.9	12
117	Anomalous origins of the right and posterior descending coronary arteries from the left anterior descending coronary artery: Unusual pattern of single coronary artery. Journal of Cardiology Cases, 2011, 3, e26-e28.	0.5	3
118	A new retrograde wiring technique for chronic total occlusion. Catheterization and Cardiovascular Interventions, 2010, 75, 117-119.	1.7	30
119	Clinical Effects of Additional Cilostazol Administration After Drug-Eluting Stent Insertion. Korean Circulation Journal, 2009, 39, 21.	1.9	5
120	Effect of Paclitaxelâ€Eluting Versus Sirolimusâ€Eluting Stents on Coronary Restenosis in Korean Diabetic Patients. Journal of Interventional Cardiology, 2008, 21, 225-231.	1.2	24
121	Comparison of the Predictors of Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic and Nondiabetic Patients. Korean Circulation Journal, 2007, 37, 530.	1.9	3
122	Comparison between the Portable Prothrombin Time Self Monitor CoaguChek XS and a Standard Laboratory Method, Sysmex CA-1500 for Monitoring Anticoagulant Therapy of Outpatients. Korean Circulation Journal, 2007, 37, 216.	1.9	2
123	The Effectiveness of Carvedilol, a New Antioxidant and Antiproliferative Beta-Blocker, on Prevention of Restenosis after Coronary Stent Implantation: a Prospective, Randomized, Multicenter Study. Sunhwan'gi, 2004, 34, 35.	0.3	2
124	The Effect of Peripheral Pulse Arrival Time(PPAT) Measurement in Evaluating Endothelial Function: a Comparison with Flow-Mediated Vasodilation(FMD). Sunhwan'gi, 2004, 34, 178.	0.3	0
125	Modes of Cell Death and Survival in Cardiomyocytes Under Various Type of Ischemic Injury. Sunhwan'gi, 2003, 33, 949.	0.3	1
126	Angiographic Outcomes and Predictors of Recurrent Restenosis after Cutting Balloon Angioplasty for the Treatment of In-Stent Restenosis. Sunhwan'gi, 2003, 33, 196.	0.3	2

#	Article	IF	CITATIONS
127	Effect of antioxidant probucol for preventing stent restenosis. Catheterization and Cardiovascular Interventions, 2002, 57, 424-428.	1.7	20
128	Combined right transradial coronary angiography and selective carotid angiography: Safety and feasibility in unselected patients. Catheterization and Cardiovascular Interventions, 2001, 53, 380-385.	1.7	16
129	Quadricuspid Aortic Valve: Report of Two Cases. Journal of the Korean Society of Echocardiography, 1999, 7, 202.	0.0	0
130	Early Outcomes of Coronary Stenting in Thrombus-Containing Lesions. Sunhwan'gi, 1998, 28, 37.	0.3	0
131	Usefulness of the Initial Electrocardiogram for Predicting the Infarct-Related Artery in Acute Inferior Myocardial Infarction. Sunhwan'gi, 1998, 28, 1096.	0.3	3
132	Plaque Morphology in Acute Coronary Syndrome: An Intravascular Ultrasound Study. Journal of the Korean Society of Echocardiography, 1998, 6, 76.	0.0	2
133	False Tendones - Echocardiographic Features and Clinical Implications. Journal of the Korean Society of Echocardiography, 1998, 6, 21.	0.0	0
134	Clinical Applications of Three-Dimensional Echocardiography. Journal of the Korean Society of Echocardiography, 1997, 5, 147.	0.0	1
135	Anterior Mitral Leaflat Perforation in Patients with Bicuspid Aortic Valve Endocarditis. Journal of the Korean Society of Echocardiography, 1997, 5, 21.	0.0	0
136	Anomalous Origin of the Left Circumflex Coronary Artery: A Report of 2 Cases and Echocardiographic Features. Journal of the Korean Society of Echocardiography, 1997, 5, 172.	0.0	0
137	Isolated Ostial left Main Stenosis Diagnosed by Transesophageal Doppler Echocardiography. Journal of the Korean Society of Echocardiography, 1997, 5, 64.	0.0	0
138	A Cases of Hypertrophic Cardiomyopathy with pathologic Q Wave in EKG. Journal of the Korean Society of Echocardiography, 1996, 4, 85.	0.0	0
139	Validation of Transesophageal Echocardiography for Measurement of Coronary Flow Reserve to Evaluation of Coronary Artery Disease. Journal of the Korean Society of Echocardiography, 1996, 4, 160.	0.0	0
140	Assessment of Left Ventricular Diastolic Dysfunction by Intraventricular Dispersion of Early Diastolic Filling. Journal of the Korean Society of Echocardiography, 1996, 4, 66.	0.0	0
141	Blood Flow Pattern of Left and Right Coronary Arteries in Patients with Coronary Arterial Disease Measured by Intracoronary Doppler-tipped Guidewire. Journal of the Korean Society of Echocardiography, 1995, 3, 138.	0.0	0
142	Echocardiographic Findings in Cardiac Tumors. Journal of the Korean Society of Echocardiography, 1995, 3, 85.	0.0	2
143	Efficacy of Interavascular Ultrasound in the Palmaz-Schatz Stent Implantation: Clinical Experience of 3 Coronary Artery Disease Patients. Journal of the Korean Society of Echocardiography, 1994, 2, 209.	0.0	0
144	Atrioventricular plane displacement in the patients with congestive heart failure. Journal of the Korean Society of Echocardiography, 1993 , 1 , 152 .	0.0	0